1A4Y image
Deposition Date 1998-02-08
Release Date 1998-10-14
Last Version Date 2024-10-16
Entry Detail
PDB ID:
1A4Y
Title:
RIBONUCLEASE INHIBITOR-ANGIOGENIN COMPLEX
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
Method Details:
Experimental Method:
Resolution:
2.00 Å
R-Value Free:
0.28
R-Value Work:
0.19
R-Value Observed:
0.19
Space Group:
P 1 21 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:RIBONUCLEASE INHIBITOR
Gene (Uniprot):RNH1
Chain IDs:A, C (auth: D)
Chain Length:460
Number of Molecules:2
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:ANGIOGENIN
Gene (Uniprot):ANG
Chain IDs:B, D (auth: E)
Chain Length:123
Number of Molecules:2
Biological Source:Homo sapiens
Primary Citation
Molecular recognition of human angiogenin by placental ribonuclease inhibitor--an X-ray crystallographic study at 2.0 A resolution.
EMBO J. 16 5162 5177 (1997)
PMID: 9311977 DOI: 10.1093/emboj/16.17.5162

Abstact

Human placental RNase inhibitor (hRI), a leucine-rich repeat protein, binds the blood vessel-inducing protein human angiogenin (Ang) with extraordinary affinity (Ki <1 fM). Here we report a 2.0 A resolution crystal structure for the hRI-Ang complex that, together with extensive mutagenesis data from earlier studies, reveals the molecular features of this tight interaction. The hRI-Ang binding interface is large and encompasses 26 residues from hRI and 24 from Ang, recruited from multiple domains of both proteins. However, a substantial fraction of the energetically important contacts involve only a single region of each: the C-terminal segment 434-460 of hRI and the ribonucleolytic active centre of Ang, most notably the catalytic residue Lys40. Although the overall docking of Ang resembles that observed for RNase A in the crystal structure of its complex with the porcine RNase inhibitor, the vast majority of the interactions in the two complexes are distinctive, indicating that the broad specificity of the inhibitor for pancreatic RNase superfamily proteins is based largely on its capacity to recognize features unique to each of them. The implications of these findings for the development of small, hRI-based inhibitors of Ang for therapeutic use are discussed.

Legend

Protein

Chemical

Disease

Primary Citation of related structures